Metastatic Colorectal Cancer
Conditions
Keywords
metastatic colorectal cancer, Patients with metastatic colorectal cancer who did not receive, systemic treatment for their metastatic disease
Brief summary
Since its introduction, 5-fluorouracil (5-FU) has been the cornerstone of treatment for metastatic colorectal cancer (mCRC). Meanwhile the oral 5FU pro-drug Capecitabine (Xeloda®) proved equivalence to 5-FU and is a well tolerated alternative combination partner for Irinotecan (XELIRI) or Oxaliplatin (XELOX) which are widely used for first line treatment of mCRC. Recent advances in molecular biology have resulted in the development of an inhibitor of the vascular endothelial growth factor (VEGF) by the monoclonal humanized antibody bevacizumab (Avastin®). XELOX or XELIRI +bevacizumab have been investigated in several trials, but not in an approach with clearly defined cross-wise XELIRI-XELOX change criteria. This trial investigates two different sequential treatment options with XELIRI/ XELOX in first and second line with the addition of bevacizumab and tries to give answer to the question if there is an optimal sequence for the benefit of the patient. This is a prospective, randomized, open-label, 2-arm pilot trial in patients with mCRC who did not receive systemic treatment for their metastatic disease. The study is designed to evaluate the efficacy of XELIRI followed by XELOX and XELOX followed by XELIRI + bevacizumab in terms of Duration of Disease Control (DDC). Patients will be treated with an established first line therapy consisting of either XELOX or XELIRI + bevacizumab. The chemotherapy treatment will be given for 6 months except prior disease progression, unacceptable toxicity or patient refusal. Bevacizumab will be given until disease progression, unacceptable toxicity or patient refusal. Capecitabine can be given in addition at the investigators' discretion until disease progression, unacceptable toxicity or patient refusal. If serious side effects occur despite adequate dose reduction, Oxaliplatin or Irinotecan should be discontinued. In case of Oxaliplatin or Irinotecan-related discontinuation Capecitabine and Bevacizumab should be continued. If Capecitabine also has to be discontinued in first line treatment bevacizumab should be continued. In case of permanent discontinuation of bevacizumab for toxicities, chemotherapy should be continued. Upon completion of first line chemotherapy patients with disease control will receive bevacizumab maintenance treatment. On investigators decision patients can receive Capecitabine as additional maintenance treatment. The primary endpoint is to determine the efficacy of a modified XELIRI + bevacizumab followed by XELOX + bevacizumab scheme at progression in comparison with the reverse sequence based on DDC. Secondary endpoints are first line progression-free survival (PFS), second line PFS, overall response rate, time to response, duration of response, overall survival, tumor assessments (based on RECIST criteria) using CT scans, MRI scans, X-ray, bone scan, clinical examination.
Interventions
DRUGCapecitabine
800mg/m2 bid d1-14 ± 1000 mg/m2 bid,days 1-14 q3w: maintenance
DRUGBevacizumab
7,5 mg/kg given on d1 q3w
DRUGOxaliplatin
130mg/m2 iv. d 1 q3w
DRUGIrinotecan
200mg/m2 iv. d 1 q3w .
Sponsors
Prof. Dr. Werner Scheithauer
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Written informed consent 2. Age \>=18 years 3. Patient must be able to comply with the protocol 4. Histologically or cytologically confirmed carcinoma of the colon and/or rectum with evidence of metastases. 5 )Diagnosis of metastatic disease according to Response Evaluation Criteria in Solid Tumours (RECIST) not more than 3 months prior to enrolment. 6\) Life Expectancy of at least 3 months 7) At least one measurable metastatic lesion (as per RECIST criteria) 8) Prior adjuvant or neo-adjuvant chemotherapy/radiotherapy allowed if completed more than 6 months before inclusion. 9) Eastern Collaborative Oncology Group (ECOG) performance score of 0 or 1 10) Adequate haematological function: absolute neutrophil count (ANC) \>= 1.5 x 109/L; platelets \>= 100 x 109/L, Hb \>= 9 g/dL 11) international normalized ratio (INR) \<=1.5 and activated partial thromboplastin time (aPTT) \<=1.5 x ULN within 7 days prior to starting study treatment 12) Adequate liver function: Serum bilirubin \<=1.5 x ULN; alkaline phosphatase and transaminases \<=2.5 x ULN (in case of liver metastases \< 5 x ULN) 13) Serum Creatinine \<=1.5 x ULN 14) Urine dipstick for proteinuria \< 2+. If urine dipstick is \>= 2+, 24- hour urine must demonstrate \<=1 g of protein in 24 hours 15) Negative serum pregnancy test within 7 days of starting study treatment in pre- menopausal women and women \< 2 years after the onset of menopause. This test has to be reconfirmed by a urine test, should the 7 days window be exceeded. Fertile women (\<2 years after last menstruation) and men must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile).
Exclusion criteria
1. Prior chemotherapeutic treatment for metastatic CRC 2. Symptomatic central nervous system (CNS) metastases 3. Significant vascular disease (e.g. aortic aneurysm potentially requiring surgical intervention, pulmonary embolism or recent peripheral arterial thrombosis) within 6 months prior start of study treatment. 4. History of haemoptysis (= a half teaspoon of bright red blood per episode) within 1 month prior start of study treatment 5. Past or current history (within the last 2 years prior to treatment start) of other malignancies (Patients with curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible). 6. Clinically significant cardiovascular disease, for example central venous access (CVA) (\<=6 months before treatment start), myocardial infarction (\<=6 months before treatment start), unstable angina, New York Heart Association (NYHA) \>= grade 2, congestive heart failure (CHF), arrhythmia requiring medication, or uncontrolled hypertension. 7. Prior history of hypertensive crisis or hypertensive encephalopathy 8. Treatment with any other investigational agent or any other biological agent (e.g.cetuximab), or participation in another clinical trial within 30 days prior to entering this study. 9. Known hypersensitivity to any of the study drugs 10. Current or recent (within 10 days of first dose of study treatment) chronic use of aspirin (\> 325 mg/day) 11. Current or recent (within 10 days prior to study treatment start) use of full-dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic (as opposed to prophylactic) purposes. 12. Evidence of bleeding diathesis or coagulopathy. 13. Serious, non healing wound, ulcer, or bone fracture. 14. Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to treatment, or anticipation of the need for major surgery during the course of the study. If central venous access device (CVAD) is required for chemotherapy administration, it should be inserted within 2 days prior to study treatment cycle. 15. Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior start of study therapy 16. History of abdominal fistula, trachea-oesophageal fistula or any grade 4 non gastrointestinal fistula, gastrointestinal perforation or intra-abdominal abscess before 1st line therapy. 17. History or evidence upon physical/neurological examination of CNS disease (unrelated to cancer) (unless adequately treated with standard medical therapy) e.g. uncontrolled seizures 18. Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment related complications 19. Patients with contraindication for cross over chemotherapy (e.g. patients treated with irinotecan based first line therapy and serious polyneuropathy \> grade 1, not feasible for oxaliplatin based cross over second line therapy, or patients treated with oxaliplatin based first line therapy and hereditary fructose intolerance not feasible for Irinotecan based cross over second line therapy) 20. Pregnancy or lactation 21. Fertile women (\<2 years after last menstruation) and men not willing to use effective means of contraception.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy Duration of Disease Control by Tumor Assessment (CT/MRI/Clinical Examination) | screening, every 8 to 9 weeks until progression, at end of treatment (other than progression), every 3 months until progression, death or up to 24 months (whatever comes first) | The primary variable was duration of disease control (DDC) and was defined as the sum of progression free survival intervals during first line and second line treatment (= time from the beginning of first line treatment until onset of progression during second line treatment). Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Second Line PFS | at progression of disease (PD) in second line therapy or at 28 days safety follow-up in cases without PD | The second line PFS was defined as the progression free survival interval during second line treatment. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). Missing onset of progression data because of refusal or because of death was replaced. If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements. |
| Overall Response Rate (Number of Participants With Response) | at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD | The rate of overall response was measured as the response rate from randomization until the day of documented complete response (CR) or partial response (PR) (whichever status is recorded first). |
| Time to Response | at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD | Time to overall response was measured from the time of randomization until the day of documented complete response (CR) or partial response (PR) (whichever status is recorded first). Patients without response were censored at the date of the last tumor assessment, the date of death or the date of refusal. |
| First Line Progression Free Survival (PFS) | at progression of disease (PD) in first line therapy or at 28 days safety follow-up in cases without PD | The first line PFS was defined as the progression free survival interval during first line treatment. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). Missing onset of progression data because of refusal or because of death was replaced. If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements. |
| Overall Survival of XELIRI Plus Bevacizumab and XELOX Plus Bevacizumab | date of death or date of last tumor assessment (28d safety f-u) in patients without death | Overall survival was measured as the time from the randomization date to the date of death. Patients without death date were censored at the date of the last tumor assessment (exception: availability of validated information about a later exitus date or a prolonged survival - in such a case the date of the follow-up assessment was either defined as the exitus date or replaced the last tumor assessment date) or the date of refusal. |
| Tumour Assessments (Based on RECIST Criteria) in 1st-line | Baseline, every 8-9 weeks, 28d Safety follow-up | Best response in first line was based on the tumor assessments (based on RECIST criteria) for target lesions and assessed by CT scans, MRI scans, X-ray, bone scan and clinical examination: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter (sum LD) of target lesions; Progressive Disease (PD), \>= 20% increase in the sum of the LD of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. |
| Tumour Assessments (Based on RECIST Criteria) in 2nd-line | Baseline, every 8-9 weeks, 28d Safety follow-up | Best response in second line was based on the tumor assessments (based on RECIST criteria) for target lesions and assessed by CT scans, MRI scans, X-ray, bone scan and clinical examination: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter (sum LD) of target lesions; Progressive Disease (PD), \>= 20% increase in the sum of the LD of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. |
| Duration of Response | at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD | Duration of overall response was measured from the time that measurement criteria are met for complete response (CR) or partial response (PR) (whichever status was recorded first) until the onset of progression. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). Missing onset of progression data because of refusal or because of death was replaced. If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements. |
Countries
Austria
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV capecitabine and irinotecan (XELIRI) plus bevacizumab (AVASTIN; BEV)
Capecitabine : 800mg/m2 bid d1-14, bevacizumab 7,5 mg/kg given on day 1 q3w combined with irinotecan 200mg/m2 iv. d 1 q3w . Bevacizumab (7.5 mg/kg q3w) ± Capecitabine (1000 mg/m2 bid, days 1-14 q3w) maintenance
At disease progression irinotecan will be replaced by oxaliplatin (arm A). Bevacizumab will be continued.
Capecitabine: 800mg/m2 bid d1-14
± 1000 mg/m2 bid,days 1-14 q3w: maintenance
Bevacizumab: 7,5 mg/kg given on d1 q3w
Irinotecan: 200mg/m2 iv. d 1 q3w . | 58 |
| B: XELOX + BEV Followed by XELIRI + BEV capecitabine and oxaliplatin (XELOX) plus bevacizumab (Avastin; BEV)
Arm B:
Capecitabine: 1000mg/m2 bid d1-14, bevacizumab 7,5 mg/kg given on d1 q3w combined with oxaliplatin 130mg/m2 iv. d 1 q3w Bevacizumab (7.5 mg/kg q3w) ± Capecitabine (1000 mg/m2 bid, days 1-14 q3w) maintenance
At disease progression oxaliplatin will be replaced by irinotecan (arm B). Bevacizumab will be continued.
Capecitabine: 1000mg/m2 bid d1-14,
Bevacizumab: 7,5 mg/kg given on d1 q3w
Oxaliplatin: 130mg/m2 iv. d 1 q3w | 62 |
| Total | 120 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| 1st-line Treatment | Adverse Event | 9 | 14 |
| 1st-line Treatment | Death | 2 | 1 |
| 1st-line Treatment | Patient condition or compliance | 6 | 4 |
| 1st-line Treatment | Physician Decision | 3 | 8 |
| 1st-line Treatment | Surgery of metastases | 2 | 1 |
| 1st-line Treatment | Withdrawal by Subject | 4 | 10 |
| 2nd-line Treatment | Adverse Event | 4 | 1 |
| 2nd-line Treatment | Lost to Follow-up | 2 | 0 |
| 2nd-line Treatment | Withdrawal by Subject | 3 | 1 |
Baseline characteristics
| Characteristic | B: XELOX + BEV Followed by XELIRI + BEV | Total | A: XELIRI + BEV Followed by XELOX + BEV |
|---|---|---|---|
| Age, Continuous | 64.06 years STANDARD_DEVIATION 9.7 | 64.53 years STANDARD_DEVIATION 9.73 | 65.03 years STANDARD_DEVIATION 9.82 |
| Race and Ethnicity Not Collected | — | 0 Participants | — |
| Region of Enrollment Austria | 62 participants | 120 participants | 58 participants |
| Sex: Female, Male Female | 19 Participants | 38 Participants | 19 Participants |
| Sex: Female, Male Male | 43 Participants | 82 Participants | 39 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 4 / 58 | 8 / 62 |
| other Total, other adverse events | 55 / 58 | 61 / 62 |
| serious Total, serious adverse events | 43 / 58 | 51 / 62 |
Outcome results
Primary
Efficacy Duration of Disease Control by Tumor Assessment (CT/MRI/Clinical Examination)
The primary variable was duration of disease control (DDC) and was defined as the sum of progression free survival intervals during first line and second line treatment (= time from the beginning of first line treatment until onset of progression during second line treatment). Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date).
Time frame: screening, every 8 to 9 weeks until progression, at end of treatment (other than progression), every 3 months until progression, death or up to 24 months (whatever comes first)
Population: ITT-Population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | Efficacy Duration of Disease Control by Tumor Assessment (CT/MRI/Clinical Examination) | 373.00 days |
| B: XELOX + BEV Followed by XELIRI + BEV | Efficacy Duration of Disease Control by Tumor Assessment (CT/MRI/Clinical Examination) | 370.00 days |
p-value: 0.967Mantel Haenszel
Secondary
Duration of Response
Duration of overall response was measured from the time that measurement criteria are met for complete response (CR) or partial response (PR) (whichever status was recorded first) until the onset of progression. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). Missing onset of progression data because of refusal or because of death was replaced. If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements.
Time frame: at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | Duration of Response | 244.0 days |
| B: XELOX + BEV Followed by XELIRI + BEV | Duration of Response | 315 days |
p-value: 0.668Mantel Haenszel
Secondary
First Line Progression Free Survival (PFS)
The first line PFS was defined as the progression free survival interval during first line treatment. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). Missing onset of progression data because of refusal or because of death was replaced. If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements.
Time frame: at progression of disease (PD) in first line therapy or at 28 days safety follow-up in cases without PD
Population: ITT-Population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | First Line Progression Free Survival (PFS) | 241 days |
| B: XELOX + BEV Followed by XELIRI + BEV | First Line Progression Free Survival (PFS) | 280 days |
p-value: 0.474Mantel Haenszel
Secondary
Overall Response Rate (Number of Participants With Response)
The rate of overall response was measured as the response rate from randomization until the day of documented complete response (CR) or partial response (PR) (whichever status is recorded first).
Time frame: at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD
Population: ITT-Population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | Overall Response Rate (Number of Participants With Response) | 32 Participants |
| B: XELOX + BEV Followed by XELIRI + BEV | Overall Response Rate (Number of Participants With Response) | 36 Participants |
p-value: 0.854Fisher Exact
Secondary
Overall Survival of XELIRI Plus Bevacizumab and XELOX Plus Bevacizumab
Overall survival was measured as the time from the randomization date to the date of death. Patients without death date were censored at the date of the last tumor assessment (exception: availability of validated information about a later exitus date or a prolonged survival - in such a case the date of the follow-up assessment was either defined as the exitus date or replaced the last tumor assessment date) or the date of refusal.
Time frame: date of death or date of last tumor assessment (28d safety f-u) in patients without death
Population: ITT-Population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | Overall Survival of XELIRI Plus Bevacizumab and XELOX Plus Bevacizumab | 593.0 days |
| B: XELOX + BEV Followed by XELIRI + BEV | Overall Survival of XELIRI Plus Bevacizumab and XELOX Plus Bevacizumab | 643 days |
p-value: 0.618Mantel Haenszel
Secondary
Second Line PFS
The second line PFS was defined as the progression free survival interval during second line treatment. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). Missing onset of progression data because of refusal or because of death was replaced. If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements.
Time frame: at progression of disease (PD) in second line therapy or at 28 days safety follow-up in cases without PD
Population: ITT-Population after cross-over
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | Second Line PFS | 129 days |
| B: XELOX + BEV Followed by XELIRI + BEV | Second Line PFS | 155 days |
p-value: 0.464Mantel Haenszel
Secondary
Time to Response
Time to overall response was measured from the time of randomization until the day of documented complete response (CR) or partial response (PR) (whichever status is recorded first). Patients without response were censored at the date of the last tumor assessment, the date of death or the date of refusal.
Time frame: at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD
Population: ITT-Population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | Time to Response | 185.0 days |
| B: XELOX + BEV Followed by XELIRI + BEV | Time to Response | 178.0 days |
p-value: 0.728Mantel Haenszel
Secondary
Tumour Assessments (Based on RECIST Criteria) in 1st-line
Best response in first line was based on the tumor assessments (based on RECIST criteria) for target lesions and assessed by CT scans, MRI scans, X-ray, bone scan and clinical examination: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter (sum LD) of target lesions; Progressive Disease (PD), \>= 20% increase in the sum of the LD of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
Time frame: Baseline, every 8-9 weeks, 28d Safety follow-up
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | Tumour Assessments (Based on RECIST Criteria) in 1st-line | Progressive Disease (PD) | 4 participants |
| A: XELIRI + BEV Followed by XELOX + BEV | Tumour Assessments (Based on RECIST Criteria) in 1st-line | Stable Disease (SD) | 21 participants |
| A: XELIRI + BEV Followed by XELOX + BEV | Tumour Assessments (Based on RECIST Criteria) in 1st-line | Partial Response (PR) | 26 participants |
| A: XELIRI + BEV Followed by XELOX + BEV | Tumour Assessments (Based on RECIST Criteria) in 1st-line | Complete Response (CR) | 2 participants |
| B: XELOX + BEV Followed by XELIRI + BEV | Tumour Assessments (Based on RECIST Criteria) in 1st-line | Complete Response (CR) | 0 participants |
| B: XELOX + BEV Followed by XELIRI + BEV | Tumour Assessments (Based on RECIST Criteria) in 1st-line | Progressive Disease (PD) | 1 participants |
| B: XELOX + BEV Followed by XELIRI + BEV | Tumour Assessments (Based on RECIST Criteria) in 1st-line | Partial Response (PR) | 30 participants |
| B: XELOX + BEV Followed by XELIRI + BEV | Tumour Assessments (Based on RECIST Criteria) in 1st-line | Stable Disease (SD) | 23 participants |
p-value: 0.792Wilcoxon (Mann-Whitney)
Secondary
Tumour Assessments (Based on RECIST Criteria) in 2nd-line
Best response in second line was based on the tumor assessments (based on RECIST criteria) for target lesions and assessed by CT scans, MRI scans, X-ray, bone scan and clinical examination: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter (sum LD) of target lesions; Progressive Disease (PD), \>= 20% increase in the sum of the LD of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
Time frame: Baseline, every 8-9 weeks, 28d Safety follow-up
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | Tumour Assessments (Based on RECIST Criteria) in 2nd-line | Complete Response (CR) | 0 participants |
| A: XELIRI + BEV Followed by XELOX + BEV | Tumour Assessments (Based on RECIST Criteria) in 2nd-line | Progressive Disease (PD) | 7 participants |
| A: XELIRI + BEV Followed by XELOX + BEV | Tumour Assessments (Based on RECIST Criteria) in 2nd-line | Stable Disease (SD) | 11 participants |
| A: XELIRI + BEV Followed by XELOX + BEV | Tumour Assessments (Based on RECIST Criteria) in 2nd-line | Partial Response (PR) | 6 participants |
| A: XELIRI + BEV Followed by XELOX + BEV | Tumour Assessments (Based on RECIST Criteria) in 2nd-line | Not available (NA) | 8 participants |
| B: XELOX + BEV Followed by XELIRI + BEV | Tumour Assessments (Based on RECIST Criteria) in 2nd-line | Not available (NA) | 1 participants |
| B: XELOX + BEV Followed by XELIRI + BEV | Tumour Assessments (Based on RECIST Criteria) in 2nd-line | Partial Response (PR) | 2 participants |
| B: XELOX + BEV Followed by XELIRI + BEV | Tumour Assessments (Based on RECIST Criteria) in 2nd-line | Progressive Disease (PD) | 8 participants |
| B: XELOX + BEV Followed by XELIRI + BEV | Tumour Assessments (Based on RECIST Criteria) in 2nd-line | Complete Response (CR) | 0 participants |
| B: XELOX + BEV Followed by XELIRI + BEV | Tumour Assessments (Based on RECIST Criteria) in 2nd-line | Stable Disease (SD) | 13 participants |
p-value: 0.371Wilcoxon (Mann-Whitney)